Laparoscopic salpingo-oophorectomy for ovarian ablation in women with hormone-sensitive breast cancer

✍ Scribed by Krishnayan Haldar; Panagiotis Giamougiannis; Charles Wilson; Robin Crawford

• Book ID: 116555303
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 106 KB
• Volume: 113
• Category: Article
• ISSN: 0020-7292
• DOI: 10.1016/j.ijgo.2010.12.013

✦ Synopsis

Abstract

Objective

To evaluate institutional experiences regarding laparoscopic salpingo‐oophorectomy in breast cancer patients and to compare the technique with gonadotropin‐releasing hormone (GnRH) analogs among premenopausal women with hormone‐sensitive breast cancer.

Methods

Between 2004 and 2009, 103 women with breast cancer underwent laparoscopic salpingo‐oophorectomy at Addenbrooke's Hospital, Cambridge, UK. All relevant medical records—including reasons for salpingo‐oophorectomy, peri‐operative events, and subsequent follow‐up—were reviewed.

Results

In the study period, 3 (2.9%) women experienced a recurrence of breast cancer but none had primary peritoneal/ovarian cancer within a median follow‐up interval of 34 months (range, 0–70 months). No operative complications were noted among these women and all of them went home on the day of their operation.

Conclusion

Laparoscopic salpingo‐oophorectomy seems to be a safe, permanent, and cost‐effective method of ovarian ablation compared with the use of GnRH analogs. Salpingo‐oophorectomy also considerably reduces the risk of subsequent ovarian/fallopian tube malignancy in this high‐risk population.